Particle beam therapy for pelvic recurrence of colorectal cancer: a registry data analysis in Japan and a systematic review

• Published in: Journal of radiation research 2023-06, Vol.64 (Supplement_1), p.i25-i33
• Main Authors: Murayama, Shigeyuki, Yamada, Shigeru, Hiroshima, Yuichi, Takiyama, Hirotoshi, Taguchi, Hiroshi, Kimoto, Takuya, Anzai, Makoto, Hagiwara, Yasuhito, Yasui, Kazuaki, Mori, Keita, Ishihara, Soichiro, Ueno, Hideki, Shimizu, Shinichi, Aoyama, Hidefumi, Tsuji, Hiroshi, Sakurai, Hideyuki
• Format: Article
• Language: English
• Subjects: Supp Pbt
• ISSN: 0449-3060; 1349-9157
• DOI: 10.1093/jrr/rrad024

The aim of this study was to investigate the efficacy and safety of particle beam therapy (PBT) with proton or carbon ion beam for pelvic recurrence of colorectal cancer (PRCC) by comparing the clinical outcomes of a dataset of prospectively enrolled patients for PBT with those from the literature, which were collected by a systematic review of external X-ray radiotherapy (XRT) and PBT. Patients with PRCC treated at 14 domestic facilities between May 2016 and June 2019 and entered the database for prospective observational follow-up were analyzed. The registry data analyzed included 159 PRCC patients treated with PBT of whom 126 (79%) were treated with carbon ion radiation therapy (CIRT). The 3-year overall survival and local control rate were 81.8 and 76.4%, respectively. Among these PRCC patients, 5.7% had Grade 3 or higher toxicity. Systematic search of PubMed and Cochrane databases published from January 2000 to September 2020 resulted in 409 abstracts for the primary selection. Twelve studies fulfilled the inclusion criteria. With one additional publication, 13 studies were selected for qualitative analysis, including 9 on XRT and 4 on PBT. There were nine XRT studies, which included six on 3D conformal radiotherapy and three on stereotactic body radiation therapy, and four PBT studies included three on CIRT and one on proton therapy. A pilot meta-analysis using literatures with median survival time extractable over a 20-month observation period suggested that PBT, especially CIRT, may be a promising treatment option for PRCC not amenable to curative resection.